1610566-94-3

Basic information

• Product Name: methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate
• Synonyms: methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate
• CAS NO: 1610566-94-3
• Molecular Weight: 400.431
• Mol File: 1610566-94-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate(1610566-94-3)
• EPA Substance Registry System: methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate(1610566-94-3)

Safety Data

• Hazardous Substances Data: 1610566-94-3(Hazardous Substances Data)

Upstream product

• 121-92-6 3-nitrobenzoic acid 
• 6307-87-5 methyl 3-bromo-5-nitrobenzoate 
• 13476-55-6 hexyl 4-aminobenzoate 
• 150-13-0 4-amino-benzoic acid 
• 111-27-3 hexan-1-ol 

Relevant articles and documents

Discovery of 14-3-3 protein-protein interaction inhibitors that sensitize multidrug-resistant cancer cells to doxorubicin and the Akt inhibitor GSK690693

14-3-3 is a family of highly conserved adapter proteins that is attracting much interest among medicinal chemists. Small-molecule inhibitors of 14-3-3 protein-protein interactions (PPIs) are in high demand, both as tools to increase our understanding of 14-3-3 actions in human diseases and as leads to develop innovative therapeutic agents. Herein we present the discovery of novel 14-3-3 PPI inhibitors through a multidisciplinary strategy combining molecular modeling, organic synthesis, image-based high-content analysis of reporter cells, and in vitro assays using cancer cells. Notably, the two most active compounds promoted the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitized multidrug-resistant cancer cells to apoptotic inducers such as doxorubicin and the pan-Akt inhibitor GSK690693, thus becoming valuable lead candidates for further optimization. Our results emphasize the possible role of 14-3-3 PPI inhibitors in anticancer combination therapies. Pièce de résistance! Multidrug resistance (MDR) is the main obstacle toward effective anticancer therapy. Herein we report the discovery of two small-molecule 14-3-3 protein-protein interaction inhibitors that promote the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitize MDR cancer cells to doxorubicin and the pan-Akt inhibitor GSK690693.